Viva Biotech hosts webinar on AI and flow chemistry transforming drug discovery synthesis
Updated
Updated · PR Newswire · Apr 21
Viva Biotech hosts webinar on AI and flow chemistry transforming drug discovery synthesis
6 articles · Updated · PR Newswire · Apr 21
The Shanghai-based event featured Dr. Jie Wu from the National University of Singapore and Dr. Kejia Ding of Viva Biotech, highlighting scalable multistep synthesis, automation, and manufacturing advances, including a 1,000 kg delivery within two months.
Speakers showcased how flow chemistry enables safer, more efficient processes for complex reactions, supporting both medicinal chemistry and large-scale manufacturing. Case studies demonstrated daily outputs exceeding 20 g and 80 g for key intermediates.
The webinar emphasized integrating AI-driven design with experimental execution, positioning flow chemistry as a bridge between digital molecule proposals and practical laboratory testing, ultimately streamlining the drug discovery and development pipeline.
As AI designs and robots synthesize drugs, what is the new role for the human chemist?
Flow chemistry delivered 1,000 kg in two months. How does its cost compare to traditional manufacturing?
How much does flow chemistry reduce the environmental footprint of drug manufacturing?
How do automated labs handle unexpected chemical reactions not predicted by AI?
Is the AI drug discovery race a winner-take-all game for tech giants?
Will proprietary 'Chemical Recipe Files' create new data silos or an open standard?
Revolutionizing Drug Development: How Viva Biotech Combines AI-Driven Design with Flow Chemistry for Faster, Safer Synthesis
Overview
In April 2026, Viva Biotech showcased how flow chemistry bridges AI-driven molecular design with scalable synthesis, enabling safer, faster drug development. Innovations like high-speed circulation flow systems improve mixing and solids handling, supporting complex, automated workflows. Viva's AI-powered Lab-in-the-Loop approach tightly integrates design, synthesis, and testing, cutting discovery time and cost. Collaborations with NVIDIA and expanded manufacturing capabilities through Langhua Pharmaceutical create a seamless path from molecule design to production. Together, these advances form an integrated platform that accelerates translating AI-generated drug candidates into real-world therapies, addressing industry demands for speed, safety, and efficiency.